Baxter គ្រោង​បំបែក​អាជីវកម្ម​ថែទាំ​តម្រងនោម​ទៅ​ជា​ក្រុមហ៊ុន​សាធារណៈ​ដាច់​ដោយ​ឡែក​ពី​គ្នា ភាគហ៊ុន​ធ្លាក់​ចុះ

• ក្រុមហ៊ុន Baxter International Inc (NYSE: BAX) announced spinning off its Renal Care and Acute Therapies global business unit into an independent, ក្រុមហ៊ុនពាណិជ្ជកម្មសាធារណៈ.

• The new kidney care company will benefit from its existing product portfolio, diverse footprint, commercial operations, and service capabilities that support its therapies delivered in the home, clinics, and intensive care unit.

• ដែលទាក់ទង: Baxter Q3 Performance underwhelms Investors, FY22 Guidance Lags Consensus.

• The business will operate in market segments totaling approximately $15 billion, estimated to grow between 3% to 4% on a compound annual basis over the next three years.

• In 2021, sales for these businesses totaled approximately $5 billion globally.

• On a pro forma basis, including Hillrom as if it were owned for the entire year, 2021 annual sales across these businesses (excluding Renal Care and Acute Therapies) were approximately $11 billion. Baxter will continue to be led by CEO Joe Almeida.

• Baxter is pursuing strategic alternatives for the BioPharma Solutions (BPS) business, including a potential sale or other separation options. BPS offers contract manufacturing services to the pharma and biotech industries.

• Baxter expects to complete the proposed spinoff in 12 to 18 months.

• សកម្មភាពតម្លៃ: BAX shares are down 6.49% at $49.15 on the last check Friday.

មើលអ្វីផ្សេងបន្ថែមទៀតរបស់ Benzinga

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។